Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199581 | 0.80 | PDK2 (0.41) | PDK2PDK4CCR1CCR5CCR8 | |
| SCHEMBL1565081 | 0.80 | CHEK1 (0.45) | — | |
| SCHEMBL13940648 | 0.80 | AHR (0.31) | — | |
| SCHEMBL1773124 | 0.80 | EGFR (0.36) | — | |
| SCHEMBL8326471 | 0.77 | KDM4E (0.33) | — | |
| SCHEMBL25302317 | 0.76 | PDK2 (0.30) | PDK2PDK4 | |
| SCHEMBL8326499 | 0.76 | EGFR (0.43) | — | |
| SCHEMBL27392500 | 0.76 | JAK1 (0.31) | — | |
| SCHEMBL8325679 | 0.76 | EGFR (0.40) | — | |
| SCHEMBL1773186 | 0.73 | IDO1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3825314-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-05-26 | — | — | EP | disclosed |
| WO-2021072487-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020015744-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | 南京明德新药研发有限公司 | 2020-01-23 | — | — | WO | disclosed |
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | PDK2 77/4885PDK4 217/4885CCR1 2595/4885 |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP3K13, WEE2 | PDK2 366/4885PDK4 536/4885CCR1 4632/4885 |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | MET, FGFR1, FGFR2 | PDK2 1267/4885PDK4 1519/4885CCR1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.